

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Rozanolixizumab for treating antibody-positive generalised myasthenia gravis
ID5092

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • UCB Pharma (rozanolixizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arthritis and Musculoskeletal Alliance • Brain and Spine Foundation • Brain Charity • Genetic Alliance UK • Muscular Dystrophy UK • Myaware • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Geriatrics Society • British Myology Society • British Neuropathological Society • British Society of Physical Rehabilitation Medicine • Chartered Society of Physiotherapy • Institute of Neurology • National Neuroscience Advisory Group • Primary Care and Community Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord UK (azathioprine, methotrexate, mycophenolate mofetil) • Advanz pharma (methotrexate) • Alexion Pharma (ravulizumab) • Alliance pharmaceuticals (neostigmine) • Argenx (efgartigimod) • Aspen (azathioprine) • Bio Products Laboratory (plasma exchange) • Biotest UK (plasma exchange) • Cipla EU (methotrexate)

Provisional stakeholder list for the evaluation of rozanolixizumab for treating antibody-positive generalised myasthenia gravis ID5092

Issue date: June 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • National Hospital for Neurology and Neurosurgery 	<ul style="list-style-type: none"> • CSL Behring UK (human immunoglobulin, plasma exchange) • Dexcel Pharma (ciclosporin) • Ennogen Pharma (azathioprine) • Grifols UK (human immunoglobulin, plasma exchange) • Healthcare pharma (azathioprine) • Hospira UK (methotrexate) • Medac GmbH (methotrexate) • Mylan (azathioprine, ciclosporin, pyridostigmine) • Napp Pharmaceutical (rituximab) • Nordic Pharma (methotrexate) • Nova laboratories (azathioprine) • Novartis (ciclosporin, mycophenolate mofetil) • Octapharma (plasma exchange) • Orion Pharma (methotrexate) • Pfizer (methotrexate, rituximab) • Roche (mycophenolate mofetil, rituximab) • Sandoz (methotrexate, mycophenolate mofetil, rituximab) • Teva UK (mycophenolate mofetil, plasma exchange) • Tillomed laboratories (azathioprine, mycophenolate mofetil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.